^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bizalimogene ralaplasmid (VGX-3100)

    i
    Other names: VGX-3100, VGX 3100, pGX-3002, ABC-3100
    Associations

    News

    Trials
    Company:
    ApolloBio, Inovio
    Drug class:
    HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
    Related drugs:
    Associations

    News

    Trials
    2d
    A Randomized, Double-Blind, Placebo-Controlled Phase III Study in China to Evaluate the Efficacy and Safety of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix (ChiCTR2300071848)
    P3, N=198, Completed, Chinese Academy of Medical Sciences Cancer Hospital; Beijing Apollo Saturn Biomedicine Technology Co. LTD | Recruiting --> Completed | N=84 --> 198
    Trial completion • Enrollment change
    |
    bizalimogene ralaplasmid (VGX-3100)
    9ms
    VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov)
    P2, N=35, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jun 2025 | Trial primary completion date: Jun 2025 --> Dec 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    bizalimogene ralaplasmid (VGX-3100)
    1year
    VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, AIDS Malignancy Consortium | Trial completion date: Jan 2027 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    bizalimogene ralaplasmid (VGX-3100)
    over1year
    VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, AIDS Malignancy Consortium | Recruiting --> Active, not recruiting | N=80 --> 35 | Trial completion date: Sep 2029 --> Jan 2027 | Trial primary completion date: Sep 2029 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    bizalimogene ralaplasmid (VGX-3100)